IL-23-话题@MedSci

#IL-23#

30篇内容 | 1963人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1479651, encodeId=807414e9651e5, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=54, createdTime=2019-10-07, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479650, encodeId=285514e9650a0, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=59, createdTime=2019-08-12, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479649, encodeId=e9d814e964946, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, objectType=article, longId=175399, objectId=02b91e539906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b91e539906, replyNumber=0, likeNumber=79, createdTime=2019-07-15, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b91e539906, moduleTitle=NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b91e539906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479648, encodeId=a14714e964804, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, objectType=article, longId=166678, objectId=b3b81666e8fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b81666e8fb, replyNumber=0, likeNumber=82, createdTime=2019-05-25, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b81666e8fb, moduleTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b81666e8fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=58, createdTime=2019-03-03, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479646, encodeId=ab0b14e964635, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, objectType=article, longId=149686, objectId=d1891496860a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1891496860a, replyNumber=0, likeNumber=104, createdTime=2018-09-28, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1891496860a, moduleTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1891496860a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479645, encodeId=dcb414e9645c2, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=79, createdTime=2018-09-20, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479644, encodeId=7bac14e9644a2, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=55, createdTime=2018-09-13, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479643, encodeId=9b5214e964393, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关, objectType=article, longId=140647, objectId=4e9114064e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9114064e97, replyNumber=0, likeNumber=69, createdTime=2018-06-14, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9114064e97, moduleTitle=GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e9114064e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479642, encodeId=133814e96425c, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！, objectType=article, longId=132345, objectId=ad62132345b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad62132345b5, replyNumber=0, likeNumber=70, createdTime=2018-03-15, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad62132345b5, moduleTitle=SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad62132345b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479641, encodeId=afef14e964133, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状, objectType=article, longId=93072, objectId=3850930e257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3850930e257, replyNumber=0, likeNumber=71, createdTime=2017-03-25, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3850930e257, moduleTitle=NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3850930e257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1479640, encodeId=c41b14e964012, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, objectTitle=强生银屑病治疗药IL-23拮抗剂临床IIb期获得成功, objectType=article, longId=53308, objectId=38ea5330848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38ea5330848, replyNumber=0, likeNumber=57, createdTime=2015-07-15, rootId=0, userName=124987a0m68(暂无昵称), userId=9e8f7562522, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38ea5330848, moduleTitle=强生银屑病治疗药IL-23拮抗剂临床IIb期获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38ea5330848)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-23

2020-05-29

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-10-07

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2019-08-12

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

NICE推荐将艾伯维的IL-23单抗risankizumab用于治疗严重斑块状银屑病

2019-07-15

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验

2019-05-25

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效

2018-09-28

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-09-20

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-09-13

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关

2018-06-14

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！

2018-03-15

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状

2017-03-25

124987a0m68(暂无昵称) (审核中...)

前往app查看评论内容

#IL-23#

强生银屑病治疗药IL-23拮抗剂临床IIb期获得成功

2015-07-15

科室
- - 订阅+
  - 更多科室
工具
服务